Literature DB >> 26647099

Triplication of 16p12.1p12.3 associated with developmental and growth delay and distinctive facial features.

Graeme A M Nimmo1, Andrea Guerin1,2, Ramses Badilla-Porras1, Dimitri J Stavropoulos3, Grace Yoon1, Melissa T Carter1.   

Abstract

The 16p12 region is particularly prone to genomic disorders due to the large number of low copy repeats [Martin et al., 2004; Nature 432:988-994]. We report two unrelated patients with de novo triplication of 16p12.1p12.3 who had developmental delay and similar facial features. Patient 1 is a 4-year-old male with a congenital heart anomaly, bilateral cryptorchidism, chronic constipation, and developmental delay. Patient 2 is a 12-year-old female with prenatally diagnosed hydronephrosis, hepatobiliary disease, failure to thrive, and developmental delay. Distinctive facial features common to both patients include short palpebral fissures, bulbous nose, thin upper vermillion border, apparently lowset ears, and large ear lobes. We compare the clinical manifestations of our patients with a previously reported patient with triplication of 16p12.2.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  abnormalities; chromosome aberrations; chromosomes; developmental disabilities; genomic; human; intellectual disability; language skills disorders; motor skills disorders; multiple; pair 16; segmental duplications

Mesh:

Year:  2015        PMID: 26647099     DOI: 10.1002/ajmg.a.37483

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  Implementation of chromosomal microarrays in a cohort of patients with intellectual disability at the Argentinean public health system.

Authors:  Lucía Daniela Espeche; Andrea Paula Solari; María Ángeles Mori; Rubén Martín Arenas; María Palomares; Myriam Pérez; Cinthia Martínez; Vanesa Lotersztein; Mabel Segovia; Romina Armando; Liliana Beatriz Dain; Julián Nevado; Pablo Lapunzina; Sandra Rozental
Journal:  Mol Biol Rep       Date:  2020-09-13       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.